Core Viewpoint - Jinfa Labi Maternal and Child Products Co., Ltd. is at risk of being delisted due to financial performance issues, specifically negative net profit and revenue below 300 million yuan in the 2024 fiscal year [2][4]. Group 1: Financial Performance - The audited financial data for 2024 shows a total profit of 70.7693 million yuan, a net profit of 49.6867 million yuan, and a net profit of -45.3168 million yuan after deducting non-recurring gains and losses, which is the lowest among the three metrics [4]. - The company's revenue for 2024 was below 300 million yuan, triggering a "delisting risk warning" effective April 24, 2025, with the stock being marked as "*ST" [2][4]. Group 2: Regulatory Compliance - According to the Shenzhen Stock Exchange listing rules, the company must disclose a risk warning announcement regarding potential delisting within one month after the end of the fiscal year in which the delisting risk warning was implemented [3][7]. - The company has already issued its first risk warning announcement on January 31, 2025, and this announcement serves as the second risk warning, with further disclosures required every ten trading days until the annual report is released [8]. Group 3: Future Risks - If the company continues to meet the criteria for delisting as outlined in the Shenzhen Stock Exchange rules, including negative net assets or receiving adverse audit opinions, it may face termination of its stock listing [5][6]. - The company has communicated with its auditing firm regarding the 2025 performance forecast, indicating no discrepancies, but final financial data will be confirmed in the official audited annual report [6]. Group 4: Information Disclosure - The company emphasizes its commitment to comply with legal and regulatory requirements for information disclosure and urges investors to refer to designated media for accurate information [9].

证券代码：002762 证券简称：*ST金比 公告编号：2026-007号 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、金发拉比妇婴童用品股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日披 露了《2024 年年度报告》，2024 年度财务数据触及《深圳证券交易所股票上市规则》第 9.3.1 条"（一）最近一个会计年度经审计的利润总额、净利润、扣除非经常性损益后 的净利润三者孰低为负值，且扣除后的营业收入低于 3 亿元"的情形，公司股票于 2025 年 4 月 24 日起被深圳证券交易所实施"退市风险警示"（股票简称前冠以"*ST"字样）。 2、公司于 2026 年 1 月 28 日在《中国证券报》《上海证券报》《证券时报》和巨潮 资讯网（http://www.cninfo.com.cn）上披露了《2025年度业绩预告》（公告编号2026-004 号），最终财务数据请以公司正式披露的经审计后的《2025 年年度报告》为准。 3、根据《深圳证券交易所股票上市规则》第 9.3.6 条：①上市公司因触及本规则 第 9.3.1 条 ...

证券代码：002762 证券简称：*ST金比 公告编号：2026-006号 登录新浪财经APP 搜索【信披】查看更多考评等级 金发拉比妇婴童用品股份有限公司 关于仲裁事项暨强制执行的进展公告 二、仲裁事项进展情况 2026年2月5日，公司委托律师接到通知，广州市中级人民法院已正式立案执行。 三、其他尚未披露的诉讼仲裁事项 截至本公告披露日，除上述仲裁事项外，公司及控股子公司不存在其他应披露而未披露的重大诉讼或仲 裁事项。 四、其他事项 公司将继续严格按照有关法律法规的规定和要求，认真履行信息披露义务，及时做好信息披露工作。敬 请广大投资者注意投资风险。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、仲裁事项情况概述 1、金发拉比妇婴童用品股份有限公司（以下简称"公司"）于2025年10月17日披露了《关于收到〈受理 仲裁申请通知书〉的公告》（2025-063号）。公司向汕头仲裁委员会提交了仲裁申请，要求被申请人一 （广州问美企业管理咨询合伙企业（有限合伙）〈曾用名：怀化问美企业管理咨询合伙企业（有限合 伙）〉）和被申请人二（黄招标）回购公司所持广东韩妃医 ...

一、仲裁事项情况概述 1、金发拉比妇婴童用品股份有限公司（以下简称"公司"）于 2025 年 10 月 17 日 披露了《关于收到<受理仲裁申请通知书>的公告》（2025-063 号）。公司向汕头仲裁委 员会提交了仲裁申请，要求被申请人一（广州问美企业管理咨询合伙企业（有限合伙） <曾用名：怀化问美企业管理咨询合伙企业（有限合伙）>）和被申请人二（黄招标）回 购公司所持广东韩妃医院投资有限公司 36%的股权，并连带向公司支付人民币 318,377,901.37 元股权回购款等。 2、2025 年 12 月 19 日，公司披露了《关于收到仲裁裁决书暨仲裁事项的进展公告》 （2025-080 号），仲裁裁决被申请人应在裁决作出后 10 日内付清股权回购款等。 3、2026 年 1 月 28 日，公司发布了《关于申请强制执行暨仲裁事项进展的公告》 （2026-003 号），披露了公司已向有管辖权的广州市中级人民法院网上提交了强制执行 申请。 二、仲裁事项进展情况 证券代码：002762 证券简称：*ST金比 公告编号：2026-006号 金发拉比妇婴童用品股份有限公司 关于仲裁事项暨强制执行的进展公告 本公司及董事 ...

证券代码：002762 证券简称：*ST金比 公告编号：2026-005号 金发拉比妇婴童用品股份有限公司 关于公司股票可能被终止上市的风险提示公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 1、金发拉比妇婴童用品股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日披 露了《2024 年年度报告》，经审计后的年度报告数据显示，公司 2024 年度利润总额为 7076.93 万元、净利润 4968.67 万元、扣除非经常性损益后的净利润-4531.68 万元，三 者孰低者扣除非经常性损益后的净利润-4531.68 万元为负值，且扣除后的营业收入低于 3 亿元。上述财务数据触及《深圳证券交易所股票上市规则》第 9.3.1 条"（一）最近 一个会计年度经审计的利润总额、净利润、扣除非经常性损益后的净利润三者孰低为负 值，且扣除后的营业收入低于 3 亿元"的情形，公司股票于 2025 年 4 月 24 日起被深 圳证券交易所实施"退市风险警示"（股票简称前冠以"*ST"字样），具体内容请详见 公司在指定信息披露媒体《证券时报》、《中国 ...

Core Viewpoint - The company, Jinfa Labi Maternal and Child Products Co., Ltd., has issued a profit warning for the fiscal year 2025, anticipating a negative net profit due to various operational challenges and investment losses [1][3]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025, with an expected net profit in negative territory [1]. - The company projects a revenue contribution of approximately 68 million yuan from the acquisitions of Zhuhai Hanfei and Zhongshan Hanfei in 2025 [2]. - The company aims to expand its product line and online channels, transitioning from maternal and infant products to family fast-moving consumer goods, which is expected to drive revenue growth [2]. Group 2: Profit Variability Reasons - The primary reason for the anticipated profit decline is the ongoing losses from the associated company, Guangdong Hanfei Hospital Investment Co., Ltd., which will require the company to recognize investment losses and provision for long-term equity investment impairment in 2025 [3]. Group 3: Arbitration and Legal Matters - The company has initiated arbitration against Guangzhou Wenmei Enterprise Management Consulting Partnership and Huang Zhaobiao for the repurchase of a 36% stake in Guangdong Hanfei Hospital Investment Co., Ltd., along with a claim for approximately 318.38 million yuan in repurchase payments [16]. - As of the announcement date, the respondents have not fulfilled their repurchase obligations, prompting the company to file for enforcement with the Guangzhou Intermediate People's Court [17].

Group 1 - The company, Jinfa Labi Maternal and Child Products Co., Ltd., has initiated arbitration proceedings against Guangzhou Wenmei Enterprise Management Consulting Partnership and Huang Zhaobiao for the repurchase of a 36% stake in Guangdong Hanfei Hospital Investment Co., Ltd., along with a claim for a repurchase amount of RMB 318,377,901.37 [2][3] - As of the announcement date, the respondents have not fulfilled their repurchase obligations, prompting the company to file for compulsory enforcement with the Guangzhou Intermediate People's Court, which is currently under review [3] - There are no other significant undisclosed litigation or arbitration matters involving the company or its subsidiaries as of the announcement date [4] Group 2 - The company has issued a performance forecast for the fiscal year 2025, indicating a projected net loss due to financial difficulties following a financial warning on its stock [8][10] - The expected revenue for 2025 is approximately RMB 68 million, primarily driven by the acquisition of Zhuhai Hanfei and Zhongshan Hanfei, along with a strategic expansion into online channels and fast-moving consumer goods [9] - The anticipated profit decline is attributed to ongoing losses from the company's investment in Guangdong Hanfei Hospital Investment Co., Ltd., necessitating the recognition of investment losses and impairment provisions [9]

Core Viewpoint - *ST Jinbi (002762.SZ) expects a net profit attributable to shareholders of the listed company for 2025 to be between -190 million and -130 million yuan, with a net profit excluding non-recurring gains and losses projected to be between -120 million and -80 million yuan, and operating revenue estimated at 350 million to 380 million yuan [1] Group 1: Revenue Changes - The revenue change is attributed to the acquisition of Zhuhai Hanfei and Zhongshan Hanfei at the end of 2024, which is expected to contribute approximately 68 million yuan to operating revenue in 2025 [1] - In 2025, the company will continue to expand its online channels and extend its product line strategy from maternal and infant products to fast-moving consumer goods for families, driving revenue growth [1] Group 2: Profit Indicators - The change in profit indicators is primarily due to the continuous losses from the associated company Guangdong Hanfei Hospital Investment Co., Ltd., which will require the company to recognize corresponding investment losses and make provisions for long-term equity investment impairment in 2025 [1]

Core Viewpoint - *ST Jinbi (002762.SZ) expects a net profit attributable to shareholders of the listed company to be between -190 million and -130 million yuan for 2025, with a revenue forecast of 350 million to 380 million yuan [1] Group 1: Revenue Changes - The revenue change is attributed to the acquisition of Zhuhai Hanfei and Zhongshan Hanfei at the end of 2024, which is expected to contribute approximately 68 million yuan to revenue in 2025 [1] - The company plans to continue its product line extension strategy and expand online channels, transitioning from maternal and infant products to fast-moving consumer goods for families, which is anticipated to drive revenue growth [1] Group 2: Profit Indicators - The profit indicators are primarily affected by the ongoing losses from the associated company Guangdong Hanfei Hospital Investment Co., Ltd., leading to the need for the company to recognize corresponding investment losses and provision for long-term equity investment impairment in 2025 [1]

证券代码：002762 证券简称：*ST 金比 公告编号：2026-004 号 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：股票交易已被实施财务类退市风险警示后的首个会计年度、预计 净利润为负值 （1）以区间数进行业绩预告 单位：万元 | 项 目 | | 本会计年度 | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 利润总额 | -20,000 | | ～ | -14,000 | 7,076.93 | | | 比上年同期下降 | 297.83% | ～ | 382.61% | | | 归属于上市公司股东的净利润 | -19,000 | | ～ | -13,000 | 5,215.06 | | | 比上年同期下降 | 349.28% | ～ | 464.33% | | | 扣除非经常性损益后的净利润 | -12,000 | | ～ | -8,000 | -4,531.68 | | ...